TEST:

Cancertrack™

The simultaneous profiling of tissue and ctDNA enhanced overall clinical utility of molecular analysis in advanced breast cancer by identifying predictive biomarkers. The integration of data from both sources allowed for comprehensive understanding of the molecular heterogeneity in breast cancer. It underscores the potential of simultaneous profiling to guide treatment decisions and improve patient outcomes.

"Datar Cancer Genetics said...that it has struck a $250 million contract with US diagnostic laboratory company Artemis DNA, which will provide Datar's cancer detection liquid biopsies in the US and Vietnam...The five-year exclusive agreement covers two Datar cancer screening and diagnostic tests: Trucheck Pragma, a noninvasive, blood-based screening test for lung, stomach, colon, pancreas, prostate, breast, and ovarian cancers; and Cancertrack, which evaluates therapy response, resistance, and cancer recurrence in patients. The assays will be initially offered as laboratory-developed tests in the US, according to Datar."